Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Adicet Bio, Inc.
< Previous
1
2
3
Next >
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
November 18, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
November 18, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024
November 16, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 06, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024
November 05, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Participate in Upcoming Investor Conferences
November 01, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 31, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome
October 16, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 30, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference
September 30, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases
September 30, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue
September 19, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 30, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
August 27, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors
August 19, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 13, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Participate in Upcoming Investor Conferences
August 01, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 31, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
July 08, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 28, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma
June 24, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis
June 05, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 31, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference
May 29, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates
May 14, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress
May 14, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
May 07, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
April 30, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
April 22, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
April 08, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.